Stefano Sestini

Stefano Sestini

Auto-generated profile, based on publicly available information

Stefano Sestini

Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
NSNicola Sverzellati
Nicola Sverzellati
MSM. Silva
M. Silva
GCG. Calareso
G. Calareso
CGCarlotta Galeone
Carlotta Galeone
AMA. Marchianò
A. Marchianò
UPUgo Pastorino
Ugo Pastorino

6 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
SSStefano Sestini
Stefano Sestini
MBMattia Boeri
Mattia Boeri
AMAlfonso Marchiano
Alfonso Marchiano
GPGiuseppe Pelosi
Giuseppe Pelosi
CGCarlotta Galeone
Carlotta Galeone
UPUgo Pastorino
Ugo Pastorino
Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

1 February 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MSMario Silva
Mario Silva
CGCarlotta Galeone
Carlotta Galeone
NSNicola Sverzellati
Nicola Sverzellati
AMAlfonso Marchianò
Alfonso Marchianò
GCGiuseppina Calareso
Giuseppina Calareso
UPUgo Pastorino
Ugo Pastorino

1 May 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
UPUgo Pastorino
Ugo Pastorino
RBRoberto Boffi
Roberto Boffi
AMAlfonso Marchianò
Alfonso Marchianò
SSStefano Sestini
Stefano Sestini
EMElena Munarini
Elena Munarini
GCGiovanni Corrao
Giovanni Corrao
The National Lung Screening Trial has achieved a 7% reduction in total mortality with low-dose computed tomography (LDCT) screening as compared with in the chest radiography arm. Other randomized trials are under way, comparing LDCT screening with no intervention. None of these studies was designed to investigate the impact of smoking habits on screening outcome. In the present study, we tested the effect of stopping smoking on the overall mortality of participants undergoing repeated LDCT screening for many years. Between 2000 and 2010, 3381 smokers aged 50 years or older were enrolled in two LDCT screening programs. On the basis of the last follow-up information, subjects were divided into two groups: current smokers throughout the screening period and former smokers. With a median follow-up time of 9.7 years and a total of 32,857 person-years (PYs) of follow-up, a total of 151 deaths were observed in the group of 1797 current smokers (17,846 PYs) versus 109 among 1584 former smokers (15,011 PYs), corresponding to mortality rates of 8.46 and 7.26 for every 1000 PYs, respectively. Compared with current smokers, former smokers had an adjusted mortality hazard ratio of 0.61 (95% confidence interval: 0.44-0.83), with a 39% reduction in mortality. A similar reduction in mortality was observed in the subset of 712 late quitters, with a hazard ratio of 0.65 (95% confidence interval: 0.44-0.96). Stopping smoking significantly reduces the overall mortality of smokers enrolled in LDCT screening programs. The beneficial effect of stopping smoking on total mortality appears to be threefold to fivefold greater than the one achieved by earlier detection in the National Lung Screening Trial.

1 July 2017 in European Journal Of Cancer Prevention
Verified
Journal Article
Closed access
MIMaurizio Infante
Maurizio Infante
SSStefano Sestini
Stefano Sestini
CGCarlotta Galeone
Carlotta Galeone
AMAlfonso Marchianò
Alfonso Marchianò
FLFabio R. Lutman
Fabio R. Lutman
UPUgo Pastorino
Ugo Pastorino
The benefits and harms of lung cancer (LC) screening with low-dose computed tomography (LDCT) are debatable. Positive results from the US National Lung Screening Trial were not evident in the European trials, possibly due to their smaller sample sizes. To address this issue, we conducted a patient-level pooled analysis of two Italian randomized controlled trials. Data from DANTE and MILD trials were combined for a total of 3640 individuals in the LDCT arm and 2909 in the control arm. LC and overall mortality were analyzed using multivariate hazard ratios (HRs) and log-rank tests stratified by study. The median follow-up was 8.2 years, with a total of 30 480 person-years in the LDCT arm and 22 157 in the control arm. A total of 192 patients developed LC in the LDCT arm and 105 in the control arm. Half of the LC cases in the LDCT arm had stage IA or IB cancer, as compared with 21% in the control arm. Overall mortality rates/100 000 person-years were 925 in the LDCT arm and 1074 in the control arm, and LC mortality rates were 299 and 357, respectively. The multivariate pooled overall mortality HR was 0.89 (95% confidence interval: 0.74–1.06) and the LC mortality HR was 0.83 (95% confidence interval: 0.61–1.12) for the LDCT arm as compared with the control arm. The present pooled analysis shows a nonsignificant 11% reduction in overall mortality in individuals undergoing LDCT screening as compared with the control arm. A pooled analysis of all European trials would be a useful contribution to assess the real benefit of LDCT screening.

1 November 2013 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
GMG. Melloni
G. Melloni
AGA.M.S. Gajate
A.M.S. Gajate
SSS. Sestini
S. Sestini
FGFrancesca Gallivanone
Francesca Gallivanone
ABA. Bandiera
A. Bandiera
PZP. Zannini
P. Zannini